MDACC Study No:2010-0696 ( NCT No: NCT01199367)
Title:A phase I/II study to evaluate the safety, tolerability, and preliminary efficacy of KW-2450 in combination with lapatinib and letrozole in subjects with advanced or metastatic breast cancer whose tumor overexpress HER2
Principal Investigator:Naoto Ueno
Treatment Agent:KW-2450; Lapatinib; Letrozole
Study Status:Terminated
Study Description:The goal of Phase 1 of this clinical research study is to find the highest
tolerable dose of KW-2450 when given in combination with lapatinib and
letrozole to patients with advanced breast cancer. The safety of this drug
combination will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Breast
Phase of Study:Phase I/Phase II
Treatment Agents:KW-2450
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Kyowa Hakko Kirin Pharma, Inc
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Naoto Ueno
Dept:Breast Medical Oncology
For Clinical Trial Enrollment:713-792-2817
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults